AC Immune SA (ACIU)
2.975
-0.02
(-0.83%)
USD |
NASDAQ |
Nov 04, 13:26
AC Immune Enterprise Value: 102.01M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 102.01M |
| October 31, 2024 | 86.18M |
| October 30, 2024 | 99.04M |
| October 29, 2024 | 103.00M |
| October 28, 2024 | 102.01M |
| October 25, 2024 | 106.95M |
| October 24, 2024 | 102.01M |
| October 23, 2024 | 105.97M |
| October 22, 2024 | 112.89M |
| October 21, 2024 | 108.93M |
| October 18, 2024 | 114.87M |
| October 17, 2024 | 122.78M |
| October 16, 2024 | 120.81M |
| October 15, 2024 | 121.80M |
| October 14, 2024 | 120.81M |
| October 11, 2024 | 133.67M |
| October 10, 2024 | 135.65M |
| October 09, 2024 | 140.59M |
| October 08, 2024 | 132.68M |
| October 07, 2024 | 141.58M |
| October 04, 2024 | 139.60M |
| October 03, 2024 | 140.59M |
| October 02, 2024 | 149.50M |
| October 01, 2024 | 176.21M |
| September 30, 2024 | 179.18M |
| Date | Value |
|---|---|
| September 27, 2024 | 176.21M |
| September 26, 2024 | 171.27M |
| September 25, 2024 | 170.28M |
| September 24, 2024 | 173.24M |
| September 23, 2024 | 167.31M |
| September 20, 2024 | 170.28M |
| September 19, 2024 | 170.28M |
| September 18, 2024 | 164.34M |
| September 17, 2024 | 147.52M |
| September 16, 2024 | 128.72M |
| September 13, 2024 | 119.82M |
| September 12, 2024 | 106.95M |
| September 11, 2024 | 107.94M |
| September 10, 2024 | 109.92M |
| September 09, 2024 | 106.95M |
| September 06, 2024 | 101.02M |
| September 05, 2024 | 112.89M |
| September 04, 2024 | 113.88M |
| September 03, 2024 | 107.94M |
| August 30, 2024 | 124.76M |
| August 29, 2024 | 124.76M |
| August 28, 2024 | 115.86M |
| August 27, 2024 | 107.94M |
| August 26, 2024 | 117.84M |
| August 23, 2024 | 109.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.6107M
Minimum
Dec 22 2022
413.52M
Maximum
Jan 15 2020
178.39M
Average
160.74M
Median
Apr 03 2024
Enterprise Value Benchmarks
| CRISPR Therapeutics AG | 3.839B |
| Addex Therapeutics Ltd | 7.218M |
| NLS Pharmaceutics Ltd | 14.90M |
| Molecular Partners AG | 26.06M |
| MoonLake Immunotherapeutics | 2.430B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.17M |
| Revenue (Quarterly) | 0.7596M |
| Total Expenses (Quarterly) | 23.94M |
| EPS Diluted (Quarterly) | -0.2543 |
| Profit Margin (Quarterly) | -3.31K% |
| Earnings Yield | -24.22% |
| Normalized Earnings Yield | -23.94 |